Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Ferree

Internal Medicine Charlotte, NC Medical Doctor

NPI 1346268323 CMS profile 15869

10635 Park Rd Ste I, Charlotte, NC 28210

Open in the dashboard

General payments

$4,411

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Ferree of Charlotte, NC is reported in the CMS Open Payments database as having received $4,411 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $158 7
2024 General $883 51
2023 General $915 48
2022 General $379 22
2021 General $393 25
2020 General $88 6
2019 General $1,596 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Ferree
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Charles Ferree were reported at $158. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Charles Ferree Internal Medicine median Middle half National median
2019 $1,596 $159 $48–$570 $163
2020 $88 $119 $33–$402 $114
2021 $393 $135 $37–$521 $132
2022 $379 $141 $42–$496 $149
2023 $915 $149 $45–$519 $160
2024 $883 $154 $47–$537 $164
2025 $158 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $526 39 payments
  2. Amgen Inc. $474 27 payments
  3. AbbVie, Inc. $362 18 payments
  4. Lilly USA, LLC $274 17 payments
  5. AstraZeneca Pharmaceuticals LP $268 17 payments
  6. Janssen Pharmaceuticals, Inc $225 13 payments
  7. Pfizer Inc. $213 16 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $198 11 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $165 9 payments
  10. GlaxoSmithKline, LLC. $149 9 payments
  11. Other $1,558 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,396 267 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $310 16 payments
  2. Ozempic $266 23 payments
  3. UBRELVY $241 11 payments
  4. QULIPTA $208 8 payments
  5. XARELTO $203 12 payments
  6. AIMOVIG $199 10 payments
  7. XIFAXAN $198 11 payments
  8. FARXIGA $198 12 payments
  9. RYBELSUS $176 14 payments
  10. Otezla $158 9 payments
  11. Other $4,194 256 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 135 drugs

Part D claims

9,389

Median for Internal Medicine: 777

Drug cost

$354,090

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 73 $87,748
Januvia Sitagliptin Phosphate Brand 18 $28,639
Jardiance Empagliflozin Brand 20 $28,072
Xarelto Rivaroxaban Brand 22 $18,484
Myrbetriq Mirabegron Brand 13 $15,400
Trulicity Dulaglutide Brand 11 $12,566
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $10,132
Rosuvastatin Calcium Generic 703 $8,475
Telmisartan Generic 239 $8,077
Synthroid Levothyroxine Sodium Brand 54 $4,903

The 10 drugs with the highest cost, of 135 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$244,970

Medicare's payments for the services billed

Medicare patients

489

Average age 75

Services billed

8,190

254 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 27%
Osteoporosis 24%
Diabetes 21%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $80
$80 — —
Wegovy
  • Novo Nordisk Inc $80
$80 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $63
$63 22 —
UBRELVY
  • AbbVie, Inc. $59
$59 — —
MOUNJARO
  • Lilly USA, LLC $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record